Next Article in Journal
Temperature-Dependent Optical Absorption and DLTS Study of As-Grown and Electron-Irradiated GaSe Crystals
Previous Article in Journal
Microstructural Stability and Creep Behavior of a Re/Ru Single-Crystal Nickel-Based Alloy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Molecular Structure and GPR35 Receptor Docking of 1,3-Phenylene Bis-Oxalamide Derivatives

by
Juan Saulo González-González
1,
José Martín Santiago-Quintana
2,
José Luis Madrigal-Angulo
3,
Lina Barragán-Mendoza
3,
Nancy E. Magaña-Vergara
3,4,
Efrén V. García-Báez
2,
Itzia Irene Padilla-Martínez
2 and
Francisco Javier Martínez-Martínez
3,*
1
Instituto de Farmacobiología, Universidad de la Cañada, Carretera Teotitlán-San Antonio Nanahuatipán, km 1.7 s/n, Teotitlán de Flores Magón, Oaxaca 68540, Mexico
2
Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Av. Acueducto s/n, Barrio La Laguna Ticomán, Ciudad de México 07340, Mexico
3
Facultad de Ciencias Químicas, Universidad de Colima, km 9 Carretera Coquimatlán-Colima, Coquimatlán Colima 28400, Mexico
4
SECIHTI, Universidad de Colima, Colima 28400, Mexico
*
Author to whom correspondence should be addressed.
Crystals 2025, 15(4), 371; https://doi.org/10.3390/cryst15040371
Submission received: 24 March 2025 / Revised: 11 April 2025 / Accepted: 15 April 2025 / Published: 17 April 2025
(This article belongs to the Section Biomolecular Crystals)

Abstract

:
A series of three 1,3-phenylene bis-oxamides 3ac, structurally related to the GPR35 receptor-agonist drug lodoxamide, has been synthesized by reacting the 1,3-phenylene bis-oxalamates 2a and 2b with amines. The obtained compounds were characterized by 1H and 13C NMR, and IR spectroscopy, they showed characteristic signals for the aromatic, N―H, and C=O groups. Molecular structure was determined using single-crystal X-ray diffraction. The supramolecular architecture is driven by N―H···O=C, N―H···N, C—H···π, and O=C···O=C interactions depicting a supramolecular helix (3a) and tapes (3bc). Intermolecular interactions were studied using Hirshfeld surface analysis, where N―H∙∙∙X (X = N, O) hydrogen bonding represents 30.2% to the surface of 3a and 17.8–18.8% to the surface of 3bc. The most energetic interactions involve the amide N—H∙∙∙O hydrogen bonding, contributing in the −113.9 to −97.0 kJ mol−1 range to the crystal energy, being more dispersive than electrostatic in nature. The molecular docking study was performed to evaluate the binding ability of 3ac compounds to the GPR35 receptor, showing a favorable binding in a similar way to lodoxamide.

1. Introduction

G protein-coupled receptor 35 (GPR35) belongs to the G protein-coupled receptor superfamily. It is a receptor highly expressed in the intestine and immune cells. It has been implicated in pathologies such as asthma, inflammation, hypertension, and diabetes [1]. The role of GPR35 in the inflammatory process as pro-inflammatory or anti-inflammatory response involves the activation of immune cells, production of cytokines, and chemotactic movements [2]. Therefore, the therapeutic potential of the GPR35 receptor can be exploited by developing synthetic ligands for its study [3].
The search for synthetic compounds that act as ligands towards the GPR35 receptor has shown that different diacid compounds such as cromolyn, nedocromil, bufrolin, pamoic acid, and lodoxamide exhibit moderate-to-high potency for such receptor [4].
Lodoxamide, commercially available as an eye drop medication, and its derivatives, lodoxamide ethyl and lodoxamide tromethamine, Figure 1, are 1,3-phenylene bis-oxalic acid-derivative agonists of the GPR35 receptor with anti-allergic activity acting as mast cell and eosinophil stabilizers [5,6]. On the other hand, 1,3-phenylene bis-oxalic derivatives (acids, esters, and amides) are versatile molecules used as supramolecular building blocks for crystal engineering and molecular recognition, since they possess N—H and C=O groups able to form intermolecular hydrogen bonds [7]. The 1,3-phenylene bis-oxalamides are compounds structurally related to lodoxamide by the substitution of the –OH of the oxalic acid with a–NHR group. In this context, we report the synthesis, molecular structure, and the in silico molecular docking affinity to the GPR35 receptor of three 1,3-phenylene bis-oxamides, 3a, 3b, and 3c, Scheme 1.

2. Materials and Methods

2.1. Materials and Methods

All compounds were purchased from Sigma-Aldrich, 3050 Spruce St., Saint Louis, MO, USA, and were used as received. The 1H and 13C were recorded on a Bruker Ultrashield plus (Ettlingen, Germany) 400 MHz instrument (400 and 100 MHz, respectively) using DMSO-d6 as the solvent and TMS as a reference. Chemical shifts (δ) and coupling constants (J) are expressed in parts per million and Hertz, respectively. Signal multiplicity is expressed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad singlet). All reactions were monitored by TLC. IR spectra were collected using a Varian 3100 FT-IR EXCALIBUR (Varian Inc., Palo Alto, CA, USA) series spectrophotometer. Melting points were measured on an Electrothermal Mel-Temp 1201D apparatus (Cole-Parmer, Vernon Hills, IL, USA).

2.2. Synthesis of Compounds

The 1,3-phenylene bis-oxalamates 2a and 2b were prepared as previously reported [7].

2.2.1. N1,N1′-(2,4,6-Trimethyl-1,3-phenylene)bis(N2-(2-morpholinoethyl)oxalamide) 3a

To a solution of 2a (0.500 g, 1.43 mmol) in methanol (30 mL), 0.416 mL (2.85 mmol) of 4-(2-aminoethyl), morpholine was added. The mixture was left at reflux for 24 h and then filtered. A white solid was obtained, which was washed with acetone to yield 0.443 g (59.9%), m.p. 234–236 °C, I.R. ν (cm−1): 3253 (N-H), 1654 (C=O). 1H NMR (DMSO-d6, δ): 10.18 (s, 2H, NH), 8.69 (t, 2H, 3J = 5.8 Hz), 7.00 (s, 1H, Ph), 1.91 (s, 3H, CH3), 2.09 (s, 6H, CH3), aminoethylmorpholine: NH-CH2 3.55 (m, 4H), CH2-N 2.48 (m, 4H), N-CH2 2.43 (m, 8H), CH2-O 3.57 (m, 8H). 13C NMR (DMSO-d6, δ): 160.5 (C9), 159.6 (C8), 133.4 (C1, C3), 132.9 (C5), 129.3 (C2), 134.5 (C4, C6), 14.2 (C17), 18.5 (C18), aminoethylmorpholine: NH-CH2 36.7, CH2-N 57.3, N-CH2 53.7, CH2-O 66.8. Anal. calcd. % (found %) for C25H38N6O6: C 57.90 (57.23), H 7.39 (7.54), N 16.21 (14.29).

2.2.2. N1,N1′-(5-(Tert-butyl)-2-methoxy-1,3-phenylene)bis(N2-(2-(piperidin-1yl)ethyl)oxalamide) 3b

To a solution of 2b (0.500 g, 1.43 mmol) in methanol (30 mL), 0.416 mL (2.85 mmol) of 2-aminoethylpiperidine was added. The mixture was left to reflux for 24 h and then filtered. A white solid was obtained to yield 0.485 g (90.1%), m.p. 234–237 °C, I.R. ν (cm−1): 3349 (N-H), 1670 (C=O). 1H NMR (DMSO-d6, δ): 9.87 (s, 2H, N7H), 8.94 (t, 2H, N10H, 3J = 5.6 Hz), 7.93 (s, 2H, Ph), 3.75 (s, 3H, O-CH3), 1.27 (s, 9H, t-but), aminoethylpiperidine: NHb-CH2 3.35 (m, 4H), CH2-N 2.48 (m, 4H), N-CH2 2.51 (m, 8H), N-CH2-CH2 1.52 (m, 8H), N-CH2-CH2-CH2 1.41 (m, 4H). 13C NMR (DMSO-d6, δ): 160.1 (C9), 158.5 (C8), 147.5 (C2), 142.6 (C5), 130.0 (C4, C6), 116.0 (C1, C3), 61.6 (C19), 35.1 (C20), 31.6 (C21), aminoethylpiperidine: N10H-CH2 39.6, CH2-N 57.1, N-CH2 54.2, N-CH2-CH2 25.9, N-CH2-CH2-CH2 24.3. Anal. calcd. % (found %) for C29H46N6O5: C 62.34 (61.47), H 8.30 (8.60), N 15.04 (14.03).

2.2.3. N1,N1′-(5-(Tert-butyl)-2-methoxy-1,3-phenylene)bis(N2-phenethyloxalamide) 3c

To a solution of 2b (0.500 g, 1.26 mmol) in methanol (30 mL), 0.318 mL (2.52 mmol) of phenethylamine was added. The mixture was left to reflux for 24 h and then filtered. A white solid was obtained to yield 0.536 g (77.6%), m.p. 156–158 °C, I.R. ν (cm−1): 3390, 3346 (N-H), 1668 (C=O). 1H NMR (DMSO-d6, δ): 9.87 (s, 2H, N7H), 9.20 (t, 2H, N10H, 3J = 5.9 Hz), 7.93 (s, 1H, Ph), 3.74 (s, 3H, O-CH3), 1.27 (s, 9H, t-but), phenethylamine: N10H-CH2 3.44 (t, 4H, 3J = 6.5 Hz), CH2-Ph 2.85 (t, 4H, 3J = 7.4 Hz), phenyl: 7.21–7.33 (m, 10H). 13C NMR (DMSO-d6, δ): 160.1 (C9), 158.5 (C8), 147.5 (C2), 140.0 (C5), 130.0 (C4, C6), 115.8 (C1, C3), 61.6 (C19), 35.1 (C20), 31.6 (C21), phenethylamine: N10H-CH2 41.4, CH2-Ph 35.1, phenyl: Ci 139.6, Co 129.0, Cm 129.3, Cp 126.8. Anal. calcd. % (found %) for C31H36N4O5: C 68.36 (67.61), H 6.66 (6.89), N 10.29 (9.91).

2.3. Molecular Docking Protocol

Molecular docking was performed using the AutoDock Vina tool implemented in UCSF Chimera version 1.16 [8]. The three-dimensional structures of the compounds 3ac were constructed using Maestro version 13.3 Schrodinger, LLC [9]. The protein structure of GPR35 was retrieved from the protein data bank with the accession code 8H8J [10]. All water molecules and the co-crystallized ligands were removed from the crystallographic structure. The grid box was defined surrounding the co-crystallized ligand lodoxamide (x = 145.78, y = 139.23, z = 162.25) with a box size of 14.510, 10.479, and 13.487 (x, y, z) within the GPR35 active site. In all simulations, the ligands were flexible, and the protein remained static. Protein–ligand interaction diagrams in 2D and 3D were generated through Discovery Studio Visualizer 2021 [11].
Validation of the protocol was performed using AutoDock Vina tool in UCSF Chimera 1.16 by redocking the co-crystallized ligand lodoxamide. The 3D structure of lodoxamide was built through Maestro 13.3 [9] and docked within the active site of GPR35 (8H8J) [10]. The grid box was centered at the crystallographic coordinates of the co-crystallized ligand (x = 145.78, y = 139.23, z = 162.25) with a box size of 14.510, 10.479, and 13.487 (x, y, z). This validation was carried out based on important interactions.

2.4. Single-Crystal X-Ray Diffraction

Single-crystal X-ray diffraction data for molecules 3ab were collected at 100(2) K and 173(2) K, respectively, on Bruker Apex II (Germany) [12], and 3c at 293 K on Nonius Kappa CCD (Bruker, Germany) diffractometers equipped with area detectors [13], both using Mo Kα radiation, λ = 0.71073 Å. Crystal data and collection parameters are listed in Table 1. The program SAINT [12] was used for integration of the diffraction profiles for 3ab, while for 3c, the program hkl2000 software was used [13]. The structures were solved with direct methods using SHELXS97 [14]. The final refinement was performed using the full-matrix least-squares methods on F2 with SHELXL2018/3 [14]. H atoms on C, N, and O were positioned geometrically and treated as riding atoms, with C−H = 0.93–0.99 Å, and with Uiso (H) = 1.2 Ueq (C). Intrinsic pseudo-disorder al the C2-Me group in compound 3a was not treated. The H atoms bonded to N atoms were freely and isotropically refined. The program Mercury 3.8 [15] was used for visualization, molecular graphics, and analysis of crystal structures. Software used to prepare material for publication was PLATON [16] in the WinGX package version 2021.3 [17]. Suitable single crystals for diffraction of 3a, 3b, and 3c were obtained by dissolving 0.5 mg of each compound in DMSO and left to evaporate the solvent. CCDC deposition numbers are 818063 (3a), 818062 (3b) and 2406249 (3c).

2.5. Hirshfeld Surface Analysis

The crystal structure of compounds 3ac was analyzed using the Hirshfeld surface [18] approach. The intermolecular interactions and their reciprocals fingerprints [19,20] were calculated in CrystalExplorer 21.5 software [21]. The individual energetic components were obtained by generating a wavefunction linking the software to the Gaussian 09 package [22] using the B3LYP/6-31G(d,p) theory. Scale factors [23] were included in the calculation, and the % contribution of individual components to the stabilization energy were also determined. The results were depicted as frameworks [23,24] in which the Eelect (electrostatic), Edisp (dispersion), and Etot (total energy) were included in a 23 [19,20] unit cell, and a 3.8 Å radius, with a tube size of 180 kJ mol−1 and 10 kJ mol−1 cut-off values.

3. Results and Discussion

3.1. Synthesis and Characterization of 3ac

The synthesis of 1,3-phenylene bis-oxamides 3ac was carried out by reacting the 1,3-phenylene bis-oxalamate 2a or 2b with the corresponding amine, Scheme 1.
For the NMR spectra, the signals were assigned according to Scheme 1, and the whole assignments are listed in Table 2. Half of the expected signals were observed in the spectra of 3ac, in agreement with a C2 symmetry axis in solution. The following 1H NMR characteristic signals were observed: the phenyl ring of the 1,3-pheylene bis-oxalamate base at 7.00 ppm for 3a, 7.93 ppm for 3b, and 7.93 ppm for 3c; the N7-H7 as a single signal at 10.18 ppm for 3a, 9.87 ppm for 3b, and 9.87 ppm for 3c. The formation of compounds 3ac was evidenced by the appearance of the N10—H10 signal in the 1H-NMR spectra as a triplet at 8.69 ppm, 8.94 ppm, and 9.20 ppm, respectively. The characteristic 13C NMR signals of 3ac are two carbonyl signals found in the 160.1–159.6 ppm range; the phenyl carbons of the 1,3-phenylene bis-oxamate base in 3a are found in the 129.3–134.5 ppm range, meanwhile, for 3bc, the phenyl carbons appeared in the 115.8–147.5 ppm range. The NMR chemical shifts are consistent with previous reports about the synthesis of similar 1,3-phenylene bis-oxamides [7,25]. IR spectroscopy showed characteristic N—H stretching bands at 3253 cm−1 for 3a, 3349 cm−1 for 3b, and 3390 cm−1 and 3346 cm−1 for 3c; meanwhile, the C=O stretching bands were 1654 cm−1 for 3a, 1670 cm−1 for 3b, and 1668 cm−1 for 3c.

3.2. Crystal Structure of 3ac

The 1,3-phenyl bis-oxalamidic compounds can adopt the endo or exo conformation according to the disposition of the oxalic groups with respect to the plane of the aromatic ring by measuring the torsion angle φ, Figure 2. In the crystal structures of compounds 3ac, the oxalic carbonyl groups adopted the characteristic anti conformation (with O=C—C=O torsion angles ranging from 161.7(3)° to 175.0(3)°, with OC—CO distances (1.528(4) Å to 1.541(5) Å), similar to those reported [7].
Compound 3a, Figure 3a, crystallized in the monoclinic system with space group C2/c; therefore, only one half of the molecule is observed. The oxalamidic groups adopt the exo–exo conformation with respect to the aromatic ring (torsion angle C2—C1—N7—C8 = −105.1(4)°). The N10—C11—C12—N13 torsion angle of the aminoethylmorpholine fragment is 170.3(3)° adopting an anti conformation. This molecule presents two adjacent sets of intramolecular hydrogen bonds [S(5)S(5)]; geometric intramolecular interactions parameters are listed in Table 3. Moreover, molecules of 3a are self-assembled in 1D via the N7-H7···O9 hydrogen bond (forming the R22(10) motif) and the C14—H14···Cg(2) interaction (Cg(2) = C1/C2/C6/C5/C6/C1), developing a 1D supramolecular meso-helix running along the c-axis, Figure 3b, similar to the related compound N′,N1′-(1,3-(2,4,6-Trimethyl)-phenyl)-bis-(N2-(2-(2-hydroxyethoxy)ethyl)oxalamide) [7]. Geometric intermolecular interaction parameters are listed in Table 4 for compounds 3ac. The turn of the helix, measured as the space between phenyl rings, is 15.78 Å, which corresponds with the length of the c-axis of the unit cell. Two-dimensional supramolecular arrangement is given by interconnected helixes along the ab plane by the formation of the N10—H10A···N13 hydrogen bond, Figure 3c.
Compounds 3b and 3c crystallized in the triclinic system with P-1 space group. The ORTEP plots are depicted in Figure 4a and Figure 5a, respectively. In both compounds, the oxalic arms adopt the exo–exo conformation, showing torsion angles C2—C1—N7—C8 = −171.2(4)° and C2—C3—N7A—C8A = −179.9(4)° for 3b; and C2—C1—N7—C8 = −178.5(3)° and C2—C3—N27—C28 = 173.1(3)° for 3c, depicting the [S(5)S(5)S(6)S(5)S(5)S(6)S(5)S(5)] set of intermolecular hydrogen bonds (similar to the starting compound 2b [7]. In 3b, one of the aminoethylpiperidine substituent groups adopts an anti conformation, with torsion angle N10A—C11A—C12A—N13A = 173.2(4)°, and the other adopts the syn conformation with torsion angle N10—C11—C12—N13 = 49.5(6)°), allowing the formation of the N10—H10···N13 S(5) intramolecular hydrogen bond. In the same way, in 3c, one of the phenethylamine substituent groups adopts the anti conformation, torsion angle N10—C11—C12—N13 = −172.2(3)°), and the other adopts the syn conformation torsion angle N30—C31—C32—N33 = 67.3(4)°.
In the 1D supramolecular architecture of 3b, a dimer is formed by the C19—H19B···O8A R22(18) interaction, and the propagation of this dimer by the N10—H10A···O8A R22(10) hydrogen bond form a supramolecular tape of molecules of 3b running along the (2–4 7) plane, Figure 4b. Interlinking the supramolecular tapes along the a-axis by dipolar C=O···C=O interactions (C8···O8A = 3.205(5) Å; C9···O8A = 3.183(6) Å; C8A···O9 = 3.219(5) Å; C9A···O9 = 3.056(5) Å) and C—H···π interactions (C12—H12D···Cg(3) = 2.68 Å; Cg(3) = C1-C6) gives rise the 2D supramolecular array, Figure 4c. Compound 3c showed the same supramolecular architecture as 3b: 1D supramolecular tape formed by C40—H40C···O29 dimers extended by N10—H10···O8 hydrogen bonds depicting R22(10) and R22(18) motifs, respectively, Figure 5b; and 2D interlinking of tapes, Figure 5c by C=O···C=O interactions (C28···O8 = 3.224(4) Å; C29···O8 = 3.109(4) Å; C8···O29 = 3.166(4) Å; C9···O29 = 3.096(4) Å). Comparing the supramolecular architectures of 3b and 3c with the crystal structure of the precursor 2b and with the related oxalamidic derivative N′,N1′-(1,3-(5-tert-butyl-2-methoxy)-phenyl)-bis-(N2-(2-hydroxyethyl)oxalamide) [7] (TEOA), it was found that both compounds also are paired by C—H···O=C interactions depicting the R22(18) motif, which is extended by C—H···O=C interactions in 2b and O—H···O=C hydrogen bonds in TEOA to develop 1D supramolecular tapes (the R22(10) motif is absent); and the 2D array in both compounds showed stacked tapes by π···π interactions and by C=O···C=O interactions, unlike 3b and 3c, where the steric effect of the aminoethylpiperidine and phenethylamine fragments avoids the formation of π···π interactions, but the C=O···C=O interactions remain.

3.3. Hirshfeld Surface (HS) Analysis

The contributions of several interactions to the HSs are differentiated between the compounds. The percentage of contribution of the most significant interactions and their reciprocals are shown in Figure 6. Among all the close interactions, H⋯H contacts represent the largest set of interactions contributing to the surface with 51.1–69.8%. The strongest interactions (A⋯H/H⋯A, A = O, N) are given by N―H∙∙∙O and N―H∙∙∙N HBs, contributing with 30.2% to the surface of 3a and 17.8–18.8% to the surface of 3bc. These interactions are shown in Figure 7 as red bright spots. Finally, the H⋯C/C⋯H interactions, represent the 5.4–19.1% of the surface.

3.4. Quantitative Interaction Energy Analysis and Energy Framework Diagrams

Quantitative interaction energies of 3ac were calculated at the B3LYP/6-31G(d,p) level of theory; selected results are listed in Table 5, and those values (Etot) smaller than −20.0 kJ mol−1 were neglected. In all crystals, the most energetic interactions involve the amide N—H∙∙∙O hydrogen bonding, assembling as R22(10) intermolecular ring motif, whose geometric parameters agree with a strong interaction. This motif contributes with −113.9 (3a), −97.0 (3b), and −110.5 (3c), kJ mol−1 to the energy in the corresponding crystal. These N―H∙∙∙O hydrogen bonding (HB) interactions are more dispersive than electrostatic in nature, contributing to the stabilization energy with 46.6–53.9% and 39.0–46.4% of Edis and Eele percent ranges, respectively. No further crystal energy results were obtained for 3a, probably due to disorder located at the C2-methyl group, even when the bright red spots marked by N10―H10∙∙∙N13 HB are observed in the HS.
In the case of 3bc, the second, third, and subsequent interaction contributors to the crystal energy are mainly composed of the interplay of C―H∙∙∙A (A = O, Cg), C―O∙∙∙CO and Cg∙∙∙Cg interactions, whose nature is mainly dispersive. Each assembly contributes 58.9–80.9% (%Edis) to stabilize the crystal network. Among Cg∙∙∙Cg interactions, the partial double bond character of the amide N30―C29 bond, Cg(1), is worth highlighting. The N30―C29 bond length is particularly short in both 3b (1.325 Å) and 3c (1.322 Å), compared with the Nn7―Cn8 (n = 0, 2) mean bond length in the anilide counterparts (1.346 ± 4). Thus, the C17―H17A∙∙∙ Cg(1) and C15―H15∙∙∙Cg(1) interactions arise in 3b and 3c, respectively, after the analysis of interaction energies. The energy values associated with C―H∙∙∙ Cg(1) interaction are −79.7 kJ mol−1 (%Edis = 74.1) and −59.2 kJ mol−1 (%Edis = 75.0), in 3b and 3c, respectively, mainly being dispersive in nature. The geometric parameters associated with this interaction are given in the footnote of Table 5.
The visual representation of the energy-framework diagrams for Eele (red), Edis (green), and Etot (blue) for a cluster of nearest-neighbor molecules is shown in Figure 8. The crystal networks of 3ac are mainly dominated by the Edis component, showing zig-zagging energy frameworks that overcome the Eelec component to give the final shape to the Etot energy framework in all cases.

3.5. Molecular Docking Analysis

Validation of the method was performed by reproducing the experimental binding of the co-crystallized ligand lodoxamide to the GPR35 receptor. Our protocol replicated the experimental binding mode of lodoxamide with an RMSD of 2.05 Å, showing hydrogen bonding interaction with Arg164, electrostatic interaction with Arg 240, π-π stacking and π-alkyl interactions with Phe163 and Leu80, respectively, and coordination with the catalytic calcium ion, Figure 9. Additionally, the calculated binding mode of lodoxamide exhibited hydrogen bonding and π-π stacking interactions with Leu258.
The molecular docking studies of 3ac showed that all ligands reached the catalytic binding site of GPR35, displaying favorable bindings. Free-binding energies ΔG (kcal/mol) are listed in Table 6. ΔG values range from −7.0 to −8.3 kcal/mol, close to the value obtained for the reference compound, lodoxamide (−8.5 kcal/mol). Our results also demonstrated that the binding modes of compounds 3ac and lodoxamide are very similar, leading to comparable accommodation within the binding site, Figure 10.
All three ligands interact with Phe163 and Leu80 amino acid residues of GPR35 through π-π stacked and π-alkyl interactions and coordinate with the catalytic calcium ion through a carbonyl group, the same as lodoxamide. However, different substituents favor unique interactions. The binding of 3a, bearing a morpholine moiety, favors the formation of a hydrogen bond between its heterocyclic oxygen and Phe161 and His168. The pyridine moiety of 3b forms alkyl–alkyl interaction with His168, Arg255 and Leu258, while the tert–butyl in 3b and 3c shows interactions of the same type with Val76, Leu77 and Leu80. Compound 3c, bearing a phenyl moiety, exhibits π–alkyl interactions with Arg255 and Leu258, and π–cation interactions with Arg240 and the catalytic calcium ion. Most of these interactions have been reported for other GPR agonists [4,10,26]. Table 7 summarizes all the interactions of the compounds 3ac with the residues of the binding site of GPR-35.
It is worth mentioning that the docked structures of 3ac adopt different conformations (bending of the N-H-R arms and O=C-C=O torsion angles different from the anti conformation, which is the most stable) compared to the X-ray structures, because they have to accommodate themselves in the GPR35 receptor binding site, which is a narrow place compared with the crystalline cell. This allows the formation of N—H···O=C, C—H···π and C—H···O intermolecular interactions with the amino acids of the binding site of the GPR35 receptor, which are responsible for the self-assembly of the 3ac molecules in the crystal cell adopting the different supramolecular architectures (helix and tapes). Additionally, it should be noted that, during the docking process, the atoms of the protein are kept rigid, which prevents induced fit of the receptor residues. This limitation is particularly relevant when docking larger molecules, such as 3ac, compared to smaller ligands like lodoxamide.

4. Conclusions

A series of 1,3 phenylene bis-oxalamides (3ac) was prepared and characterized using 1H and 13C NMR, IR spectroscopy and single-crystal X-ray diffraction. The supramolecular architecture of 3a is driven by N—H···O=C and N—H···N hydrogen bonds depicting a meso-helix; meanwhile, 3b and 3c showed C—H···π, and O=C···O=C interactions depicting supramolecular tapes (3bc). According to Hirshfeld surface analysis, N―H∙∙∙X (X = N, O) hydrogen bonding represents 30.2% to the surface of 3a and 17.8–18.8% to the surface of 3bc. The most energetic interactions involve the amide N—H∙∙∙O hydrogen bonding, contributing in the −113.9 to −97.0 kJ mol−1 range to the crystal energy, being more dispersive than electrostatic in nature. The compounds showed favorable binding to the catalytic binding site of the GPR35 receptor, in a similar mode of binding and accommodation compared with lodoxamide.

Author Contributions

F.J.M.-M., I.I.P.-M. and J.S.G.-G. conceptualized the study. J.L.M.-A. and L.B.-M. developed Docking. J.S.G.-G., I.I.P.-M. and F.J.M.-M. performed research. J.M.S.-Q. and I.I.P.-M. provided Hirshfeld surface analysis. E.V.G.-B. and N.E.M.-V. collected X-ray diffraction. F.J.M.-M., J.S.G.-G. and I.I.P.-M. wrote, reviewed and edited the manuscript. F.J.M.-M. and I.I.P.-M. supervised the study. F.J.M.-M. and I.I.P.-M. confirm the authenticity of all the raw data. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Acknowledgments

The present study was supported by SIP-IPN-20250238, Universidad de la Cañada and Universidad de Colima.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. MacKenzie, A.E.; Lappin, J.E.; Taylor, D.L.; Nicklin, S.A.; Milligan, G. GPR35 as a Novel Therapeutic Target. Front. Endocrinol. 2011, 2, 68. [Google Scholar] [CrossRef] [PubMed]
  2. Wu, Y.; Zhang, P.; Fan, H.; Zhang, C.; Yu, P.; Liang, X.; Chen, Y. GPR35 Acts a Dual Role and Therapeutic Target in Inflammation. Front. Immunol. 2023, 14, 1254446. [Google Scholar] [CrossRef] [PubMed]
  3. Shore, D.M.; Reggio, P.H. The Therapeutic Potential of Orphan GPCRs, GPR35 and GPR55. Front. Pharmacol. 2015, 6, 69. [Google Scholar] [CrossRef]
  4. MacKenzie, A.E.; Caltabiano, G.; Kent, T.C.; Jenkins, L.; McCallum, J.E.; Hudson, B.D.; Nicklin, S.A.; Fawcett, L.; Markwick, R.; Charlton, S.J.; et al. The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35. Mol. Pharmacol. 2014, 85, 91–104. [Google Scholar] [CrossRef] [PubMed]
  5. Song, Z.; Lu, D.; Sun, J.; Ye, Y.; Fang, J.; Wang, K.; Guo, S.; Zhang, Q.; He, X.; Xie, X.; et al. Discovery of a Novel GPR35 Agonist with High and Equipotent Species Potency for Oral Treatment of IBD. Bioorg. Med. Chem. 2023, 96, 117511. [Google Scholar] [CrossRef]
  6. Cao, M.; Gao, Y. Mast Cell Stabilizers: From Pathogenic Roles to Targeting Therapies. Front. Immunol. 2024, 15, 1418897. [Google Scholar] [CrossRef]
  7. González-González, J.S.; Martínez-Martínez, F.J.; Peraza-Campos, A.L.; Rosales-Hoz, M.d.J.; García-Báez, E.V.; Padilla-Martínez, I.I. Supramolecular Architectures of Conformationally Controlled 1,3-Phenyl-Dioxalamic Molecular Clefts through Hydrogen Bonding and Steric Restraints. CrystEngComm 2011, 13, 4748–4761. [Google Scholar] [CrossRef]
  8. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef]
  9. Schrödinger, L. Maestro, Version 13.3; Schödinger Release 2025-1; Schrödinger: New York, NY, USA, 2025. Available online: https://www.schrodinger.com (accessed on 25 February 2025).
  10. Duan, J.; Liu, Q.; Yuan, Q.; Ji, Y.; Zhu, S.; Tan, Y.; He, X.; Xu, Y.; Shi, J.; Cheng, X.; et al. Insights into Divalent Cation Regulation and G13-Coupling of Orphan Receptor GPR35. Cell Discov. 2022, 8, 135. [Google Scholar] [CrossRef]
  11. Dassault Systèmes. BIOVIA Discovery Studio Visualizer 2021; Dassault Systèmes: Paris, France, 2025; Available online: https://www.3ds.com/products/biovia (accessed on 25 February 2025).
  12. Bruker. APEX2, SAINT; Bruker AXS Inc.: Madison, WI, USA, 2006. [Google Scholar]
  13. Otwinowski, Z.; Minor, W. Processing of X-Ray Diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Elsevier: Amsterdam, The Netherlands, 1997; Volume 276, pp. 307–326. [Google Scholar] [CrossRef]
  14. Sheldrick, G.M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. Sect. C Struct. Chem. 2015, 71, 3–8. [Google Scholar] [CrossRef]
  15. Macrae, C.F.; Bruno, I.J.; Chisholm, J.A.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Rodriguez-Monge, L.; Taylor, R.; Van De Streek, J.; Wood, P.A. New Features for the Visualization and Investigation of Crystal Structures. J. Appl. Crystallogr. 2008, 41, 466–470. [Google Scholar] [CrossRef]
  16. Spek, A.L. PLATON SQUEEZE: A Tool for the Calculation of the Disordered Solvent Contribution to the Calculated Structure Factors. Acta Crystallogr. Sect. C Struct. Chem. 2015, 71, 9–18. [Google Scholar] [CrossRef] [PubMed]
  17. Farrugia, L.J. WinGX and ORTEP for Windows: An Update. J. Appl. Crystallogr. 2012, 45, 849–854. [Google Scholar] [CrossRef]
  18. Spackman, M.A.; Jayatilaka, D. Hirshfeld Surface Analysis. CrystEngComm 2009, 11, 19–32. [Google Scholar] [CrossRef]
  19. McKinnon, J.J.; Jayatilaka, D.; Spackman, M.A. Towards Quantitative Analysis of Intermolecular Interactions with Hirshfeld Surfaces. Chem. Commun. 2007, 37, 3814–3816. [Google Scholar] [CrossRef]
  20. Spackman, M.A.; McKinnon, J.J. Fingerprinting Intermolecular Interactions in Molecular Crystals. CrystEngComm 2002, 4, 378–392. [Google Scholar] [CrossRef]
  21. Spackman, P.R.; Turner, M.J.; McKinnon, J.J.; Wolff, S.K.; Grimwood, D.J.; Jayatilaka, D.; Spackman, M.A. CrystalExplorer: A Program for Hirshfeld Surface Analysis, Visualization and Quantitative Analysis of Molecular Crystals. J. Appl. Crystallogr. 2021, 54, 1006–1011. [Google Scholar] [CrossRef]
  22. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; et al. Gaussian 09, Revision, A.02; Gaussian, Inc.: Wallingford, CT, USA, 2009. [Google Scholar]
  23. Mackenzie, C.F.; Spackman, P.R.; Jayatilaka, D.; Spackman, M.A. CrystalExplorer Model Energies and Energy Frameworks: Extension to Metal Coordination Compounds, Organic Salts, Solvates and Open-Shell Systems. IUCrJ 2017, 4, 575–587. [Google Scholar] [CrossRef]
  24. Turner, M.J.; Thomas, S.P.; Shi, M.W.; Jayatilaka, D.; Spackman, M.A. Energy Frameworks: Insights into Interaction Anisotropy and the Mechanical Properties of Molecular Crystals. Chem. Commun. 2015, 51, 3735–3738. [Google Scholar] [CrossRef]
  25. Padilla-Martínez, I.I.; Martínez-Martínez, F.J.; Guillén-Hernández, C.I.; Chaparro-Huerta, M.; Cabrera-Pérez, L.C.; Gómez-Castro, C.Z.; López-Romero, B.A.; García-Báez, E.V. Switching from Twisted to Planar Oxamide Molecular Cavities through Intramolecular Three Centered Hydrogen Bonding. Arkivoc 2005, 2005, 401–415. [Google Scholar] [CrossRef]
  26. Zhao, P.; Lane, T.R.; Gao, H.G.L.; Hurst, D.P.; Kotsikorou, E.; Le, L.; Brailoiu, E.; Reggio, P.H.; Abood, M.E. Crucial Positively Charged Residues for Ligand Activation of the GPR35 Receptor. J. Biol. Chem. 2014, 289, 3625–3638. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Lodoxamide derivatives.
Figure 1. Lodoxamide derivatives.
Crystals 15 00371 g001
Scheme 1. Synthesis of 1,3-phenylene bis-oxamides 3ac.
Scheme 1. Synthesis of 1,3-phenylene bis-oxamides 3ac.
Crystals 15 00371 sch001
Figure 2. Endo–exo conformations according to the torsion angle φ.
Figure 2. Endo–exo conformations according to the torsion angle φ.
Crystals 15 00371 g002
Figure 3. (a) ORTEP diagram of 3a with the displacement ellipsoid drawn at 70% probability, showing intramolecular interactions. (b) 1D supramolecular meso-helix of 3a formed by N—H···O=C hydrogen bonds and C—H···π intermolecular interactions. (c) Interlinking of supramolecular helixes of 3a by N-H···N intermolecular hydrogen bonds. Some H atoms have been omitted for clarity. Dashed lines represent hydrogen bonds or non-covalent interactions.
Figure 3. (a) ORTEP diagram of 3a with the displacement ellipsoid drawn at 70% probability, showing intramolecular interactions. (b) 1D supramolecular meso-helix of 3a formed by N—H···O=C hydrogen bonds and C—H···π intermolecular interactions. (c) Interlinking of supramolecular helixes of 3a by N-H···N intermolecular hydrogen bonds. Some H atoms have been omitted for clarity. Dashed lines represent hydrogen bonds or non-covalent interactions.
Crystals 15 00371 g003
Figure 4. (a) ORTEP diagram of 3b with the displacement ellipsoid drawn at 50% probability, showing intramolecular interactions. (b) 1D supramolecular tape of 3b formed by C—H···O intermolecular interactions showing the R22(18) motif. (c) Interlinking of supramolecular tapes of 3b by dipolar C=O···O=C and C—H···π intermolecular interactions. Some H atoms have been omitted for clarity. Dashed lines represent hydrogen bonds or non-covalent interactions.
Figure 4. (a) ORTEP diagram of 3b with the displacement ellipsoid drawn at 50% probability, showing intramolecular interactions. (b) 1D supramolecular tape of 3b formed by C—H···O intermolecular interactions showing the R22(18) motif. (c) Interlinking of supramolecular tapes of 3b by dipolar C=O···O=C and C—H···π intermolecular interactions. Some H atoms have been omitted for clarity. Dashed lines represent hydrogen bonds or non-covalent interactions.
Crystals 15 00371 g004
Figure 5. (a) ORTEP diagram of 3c with the displacement ellipsoid drawn at 50% probability, showing intramolecular interactions. (b) 1D supramolecular tape of 3c formed by C-H···O intermolecular interactions showing the R22(18) motif. (c) Interlinking of supramolecular tapes of 3c by dipolar C=O···O=C intermolecular interactions. Some H atoms have been omitted for clarity. Dashed lines represent hydrogen bonds or non-covalent interactions.
Figure 5. (a) ORTEP diagram of 3c with the displacement ellipsoid drawn at 50% probability, showing intramolecular interactions. (b) 1D supramolecular tape of 3c formed by C-H···O intermolecular interactions showing the R22(18) motif. (c) Interlinking of supramolecular tapes of 3c by dipolar C=O···O=C intermolecular interactions. Some H atoms have been omitted for clarity. Dashed lines represent hydrogen bonds or non-covalent interactions.
Crystals 15 00371 g005
Figure 6. Percentage of contribution of the most significant interactions and their reciprocals in compounds 3ac. N∙∙∙X (X = C, N, O).
Figure 6. Percentage of contribution of the most significant interactions and their reciprocals in compounds 3ac. N∙∙∙X (X = C, N, O).
Crystals 15 00371 g006
Figure 7. Hirshfeld surfaces (HS) of 3ac.
Figure 7. Hirshfeld surfaces (HS) of 3ac.
Crystals 15 00371 g007
Figure 8. Energy frameworks of 3ac. (a) Electrostatic; (b) Dispersive; (c) Total.
Figure 8. Energy frameworks of 3ac. (a) Electrostatic; (b) Dispersive; (c) Total.
Crystals 15 00371 g008
Figure 9. Representation of the interactions in 2D of lodoxamide co-crystallized (a), lodoxamide docked (b), and (c) the superimposition of both (co-crystallized in yellow and docked in blue) within the GPR35 active site for validation purposes. Interactions are color-coded: green, hydrogen bonds; dark pink, π-π interactions; pale pink, alkyl-π interactions; orange, electrostatic and cation-π interactions; gray, metal coordination. CA; calcium ion.
Figure 9. Representation of the interactions in 2D of lodoxamide co-crystallized (a), lodoxamide docked (b), and (c) the superimposition of both (co-crystallized in yellow and docked in blue) within the GPR35 active site for validation purposes. Interactions are color-coded: green, hydrogen bonds; dark pink, π-π interactions; pale pink, alkyl-π interactions; orange, electrostatic and cation-π interactions; gray, metal coordination. CA; calcium ion.
Crystals 15 00371 g009
Figure 10. Binding poses at GPR35 active site of the target compounds. Left panel: 3D ligand interaction diagram of (a) 3a, (c) 3b, and (e) 3d. Right panel: superimposition of (b) 3a, (d) 3b, and (f) 3d with lodoxamide (yellow) within the GPR35 active site.
Figure 10. Binding poses at GPR35 active site of the target compounds. Left panel: 3D ligand interaction diagram of (a) 3a, (c) 3b, and (e) 3d. Right panel: superimposition of (b) 3a, (d) 3b, and (f) 3d with lodoxamide (yellow) within the GPR35 active site.
Crystals 15 00371 g010
Table 1. Crystallographic parameters for compounds 3a, 3b, and 3c at 293 K.
Table 1. Crystallographic parameters for compounds 3a, 3b, and 3c at 293 K.
3a3b3c
Crystal Data
Chemical formulaC25H38N6O6C29H46N6O5C31H36N4O5
Mw/g mol−1518.61558.72544.64
Crystal system, space groupMonoclinic, C2/cTriclinic, P-1Triclinic, P-1
a, b, c (Å)24.772(6), 8.0171(19), 15.789(4)9.1930(5), 10.194(5), 16.8920(5)9.2580(6), 10.3050(6), 15.7970(6)
α, β, γ (°)125.836(3)101.205(5), 103.435(5), 98.086(5)92.554(5), 103.669(5), 106.186(5)
V3)2542.1(11)1481.4(7)1396.48(14)
Z422
Dx, g cm−31.3551.2481.295
µ (mm−1)0.100.090.09
Crystal size (mm)0.3 × 0.2 × 0.10.4 × 0.3 × 0.30.3 × 0.2 × 0.1
Data Collection
DiffractometerBruker Apex IIBruker Apex IIKappa CCD
Radiation typeMo Kα
(λ = 0.71073)
Mo Kα
(λ = 0.71073)
Mo Kα
(λ = 0.71073)
No. of measured, independent and
observed [I > 2σ(I)] reflections
14,192, 3068, 270616,141, 5876, 316921,430, 4868, 3075
Rint0.0530.0970.11
Index ranges−32 ≤ h ≤ 31, −10 ≤ k ≤ 10, −20 ≤ l ≤ 20−11 ≤ h ≤ 11, −12 ≤ k ≤ 12, −21 ≤ l ≤ 22−10 ≤ h ≤ 10, −12 ≤ k ≤ 12, −18 ≤ l ≤ 18
Refinement
R[F2 > 2σ(F2)], wR(F2), S0.098, 0.199, 1.300.100, 0.321, 1.020.061, 0.174, 1.05
No. of reflections306858764868
No. of parameters170377381
No. of restraints000
Δρmax, Δρmin (e Å−3)0.55, −0.550.46, −0.550.33, −0.28
Table 2. 1H and 13C NMR chemical shifts in DMSO-d6 of compounds 3ac (δ = ppm).
Table 2. 1H and 13C NMR chemical shifts in DMSO-d6 of compounds 3ac (δ = ppm).
1H-NMR
H4,6H5H7H10H17H18H19H21
3a a---7.0010.188.691.912.09------
3b b7.93---9.878.94------3.751.27
3c c7.93---9.879.20------3.741.27
13C-NMR
C1,3C2C4,6C5C8C9C17C18C19C20C21
3a d132.9129.3134.5132.9159.6160.514.218.5---------
3b e116.0147.5130.0142.6158.5160.1------61.635.131.6
3c f115.8147.5130.0140.0158.5160.1------61.635.136.1
a NH-CH2 3.55, CH2-N 2.48; morpholine: N-CH2 2.43, CH2-O 3.57. b NH-CH2 3.35, CH2-N 2.48; piperidine: N-CH2 2.51, N-CH2CH2 1.52, N-CH2CH2CH2 1.41. c NH-CH2 3.44, CH2-Ph; phenyl: 7.21–7.33. d NH-CH2 36.7, CH2-N 57.3; morpholine: N-CH2 53.7, CH2-O 66.8. e NH-CH2 39.6, CH2N 57.1; piperidine: N-CH2 54.2, N-CH2CH2 25.9, N-CH2CH2CH2 24.3. f NHb-CH2 41.4, CH2-Ph 35.1, phenyl: Ci 139.6, Co 129.0, Cm 129.3, Cp 126.8.
Table 3. Intramolecular interactions in 3ac.
Table 3. Intramolecular interactions in 3ac.
D—H···AD—H
(Å)
H···A
(Å)
D···A
(Å)
D—H···A
(°)
3a
N7—H7A···O90.862.342.72(3)107
N10—H10A···O80.862.392.73(3)104
3b
N7—H7···O20.85(5)2.26(5)2.71(5)114(4)
N7—H7···O90.85(5)2.26(5)2.64(5)108(4)
N7A—H7A···O20.79(5)2.38(5)2.73(5)108(4)
N7A—H7A···O9A0.79(5)2.21(5)2.64(5)115(4)
N10—H10···O80.69(7)2.46(6)2.72(5)105(5)
N10—H10···N130.69(7)2.53(6)2.84(6)111(6)
C4—H4···O8A0.932.312.93(5)124
C6—H6···O80.932.342.94(5)122
3c
N7—H7···O90.77(3)2.24(3)2.64(3)114(4)
N7—H7···O390.77(3)2.38(3)2.74(4)110(3)
N10—H10···O80.70(3)2.41(3)2.73(3)110(3)
N27—H27···O290.79(3)2.26(3)2.66(4)113(3)
N27—H27···O390.79(3)2.33(3)2.71(3)112(3)
N30—H30···O280.73(3)2.34(3)2.69(4)111(3)
C6—H19···080.932.322.93(4)123
C4—H21···0280.932.332.94(4)123
Table 4. Intermolecular interactions in 3ac.
Table 4. Intermolecular interactions in 3ac.
D—H···ASymmetry CodeD—HH···AD···AD—H···A
3a
N7—H7A···O9−x, 2 − y, −z0.862.042.85(4)159
N10—H10A··N131/2 − x, 1/2 + y, 1/2 − z0.862.142.94(5)155
C14—H14B···Cg(2)−x, 2 − y, −z 2.84 171
3b
N10A—H10A··O8A2 − x, 1 − y, −z0.862.223.00(5)152
C19—H19B···O9−x, −y, −z0.962.513.45(5)165
C12—H12D···Cg(3)1 + x, y, z 2.68 165
3c
N10—H10 ∙∙∙ O83 − x, 1 − y, −z0.702.34(3)2.98(4)155(3)
C40—H40C∙∙∙O291 − x, −y, −z0.962.463.32(4)150
Table 5. Calculated interaction energies (kJ mol−1), %Ecomp contributions to stabilization energy for selected HB and close contacts in compounds 3ac.
Table 5. Calculated interaction energies (kJ mol−1), %Ecomp contributions to stabilization energy for selected HB and close contacts in compounds 3ac.
MotifInteractionEeleEpolEdisErepEtot%Eele a%Edis aR b
3a
R22(10)N7―H7∙∙∙O987.913.488.375.8113.946.446.68.20
3b
R22(10)N10―H10∙∙∙O837.86.952.30.097.039.053.912.79
Cg(3)∙∙∙Cg(3) c
C44―H44C∙∙∙O9
Cg(3)∙∙∙C8O8
20.43.9101.640.685.316.280.75.96
C17―H17A∙∙∙Cg(1) d25.43.382.031.079.722.974.17.24
C29―O29∙∙∙C9
C8―O8∙∙∙C29
C32―H32B∙∙∙Cg(3) c
16.93.076.032.663.317.679.39.19
R22(18)C40―H40A∙∙∙O2925.33.643.022.949.035.159.88.18
3c
R22(10)
C(19)
N10―H10∙∙∙O8
C34―H34C∙∙∙Cg(2) e
47.57.555.50.0110.543.050.212.26
C43―H43A∙∙∙O925.34.1108.948.090.318.378.75.36
C15―H15∙∙∙Cg(1) f19.13.068.331.159.221.275.68.27
R22(18)C40―H40C∙∙∙O2928.94.948.422.659.535.158.98.07
C29―O29∙∙∙C8
C8―O8∙∙∙C29
C31―H31B∙∙∙Cg(3)
12.62.363.021.856.116.280.99.26
a The % contribution of Ecomp (%Ecomp) is calculated through (Ecomp/Estab) × 100 where Estab = Eele + Epol + Edisp. b R = distance between centroids in Å. c Cg(3) is the centroid of the C1-C6 ring. d Cg(1) is the centroid of the N30―C29 bond, C17―H17A∙∙∙ Cg(1) distance of 2.954 Å, angle of 127.2°, N30―C29 length = 1.325 Å (−x, 1 − y, 2 − z). e Cg(2) is the centroid of the C13-C18 ring. f Cg(1) is the centroid of the N30―C29 bond, N30―C29 length = 1.322 Å, H15∙∙∙Cg(1) 2.805 Å, 147.4°.
Table 6. Free-binding energies ΔG (kcal/mol) of compounds 3ac docked into the active site of GPR35.
Table 6. Free-binding energies ΔG (kcal/mol) of compounds 3ac docked into the active site of GPR35.
CompoundΔG (kcal/mol)
3a−8.3
3b−7.0
3c−7.2
Lodoxamide−8.5
Table 7. Interactions type of compounds 3ac with the different residues of GPR-35.
Table 7. Interactions type of compounds 3ac with the different residues of GPR-35.
ResidueCompound
Lodoxamide3a3b3c
Val76------Alkyl–alkylAlkyl–alkyl
Val77------Alkyl–alkylAlkyl–alkyl
Leu80π–alkylπ–alkylπ–alkyl,
alkyl–alkyl
π–alkyl,
alkyl–alkyl
Tyr96---π–alkyl------
Arg100---------HB
Phe161---Carbon hydrogen bond------
Phe163π–π stackedπ–π stackedπ–π stackedπ–π stacked
Arg164HB; electrostatic---------
His168Carbon hydrogen bond---Alkyl–alkyl---
Arg240Electrostatic------π–cation
Arg255------Alkyl–alkylπ–alkyl
Leu258HB;
π–π stacked
π–alkylAlkyl–alkylπ–alkyl
Tyr259---π–alkyl------
Ser262---HBHBHB
Ca402Metal coordination; electrostaticMetal coordinationMetal coordinationMetal coordination; π-cation
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

González-González, J.S.; Santiago-Quintana, J.M.; Madrigal-Angulo, J.L.; Barragán-Mendoza, L.; Magaña-Vergara, N.E.; García-Báez, E.V.; Padilla-Martínez, I.I.; Martínez-Martínez, F.J. Molecular Structure and GPR35 Receptor Docking of 1,3-Phenylene Bis-Oxalamide Derivatives. Crystals 2025, 15, 371. https://doi.org/10.3390/cryst15040371

AMA Style

González-González JS, Santiago-Quintana JM, Madrigal-Angulo JL, Barragán-Mendoza L, Magaña-Vergara NE, García-Báez EV, Padilla-Martínez II, Martínez-Martínez FJ. Molecular Structure and GPR35 Receptor Docking of 1,3-Phenylene Bis-Oxalamide Derivatives. Crystals. 2025; 15(4):371. https://doi.org/10.3390/cryst15040371

Chicago/Turabian Style

González-González, Juan Saulo, José Martín Santiago-Quintana, José Luis Madrigal-Angulo, Lina Barragán-Mendoza, Nancy E. Magaña-Vergara, Efrén V. García-Báez, Itzia Irene Padilla-Martínez, and Francisco Javier Martínez-Martínez. 2025. "Molecular Structure and GPR35 Receptor Docking of 1,3-Phenylene Bis-Oxalamide Derivatives" Crystals 15, no. 4: 371. https://doi.org/10.3390/cryst15040371

APA Style

González-González, J. S., Santiago-Quintana, J. M., Madrigal-Angulo, J. L., Barragán-Mendoza, L., Magaña-Vergara, N. E., García-Báez, E. V., Padilla-Martínez, I. I., & Martínez-Martínez, F. J. (2025). Molecular Structure and GPR35 Receptor Docking of 1,3-Phenylene Bis-Oxalamide Derivatives. Crystals, 15(4), 371. https://doi.org/10.3390/cryst15040371

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop